TA Associates-backed OmniActive explores $200-300 million IPO at $1 bn valuation

The IPO plan follows several unsuccessful attempts to raise private capital, as macroeconomic headwinds and geopolitical conflicts weighed on investor sentiment. If the IPO goes as planned, it would make OmniActive the first pure-play nutraceutical company to list on the exchanges.